Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1225

Sort by

Sort Order Select

Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Blood (2020) 136 (4): 468–479.

https://doi.org/10.1182/blood.2019004147

Published: 2020

Includes: Supplemental data

Journal Articles

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

Wen-Bing Ma, Xiao-Han Wang, Chang-Yan Li, Huan-Huan Tian, Jie Zhang, Jun-Jie Bi, Guang-Ming Ren, Shou-Song Tao, Xian Liu, Wen Zhang, Dong-Xu Li, Hui Chen, Yi-Qun Zhan, Miao Yu, Chang-Hui Ge, Xiao-Ming Yang, Rong-Hua Yin

Blood (2020) 135 (25): 2302–2315.

https://doi.org/10.1182/blood.2019003867

Published: 2020

Includes: Supplemental data

Journal Articles

A master erythroid regulator gets its own GPS

Lily Jun-shen Huang, James J. Bieker

Blood (2020) 135 (25): 2209–2210.

https://doi.org/10.1182/blood.2020005882

Published: 2020

Journal Articles

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Panagiotis Efentakis, PhD, Ioanna Andreadou, PhD, Panagiota-Efstathia Nikolaou, PhD, Claudius Witzler, Svenja Siemer, Eftathios Kastritis, Philip Wenzel, MD PhD, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 3797.

https://doi.org/10.1182/blood-2019-123522

Published: 2019

Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD

Blood (2019) 134 (Supplement_1): 3803.

https://doi.org/10.1182/blood-2019-128981

Published: 2019

Journal Articles

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Blood (2019) 134 (Supplement_1): 5493.

https://doi.org/10.1182/blood-2019-125447

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

The Role of Proteasome Activator PA28α in Multiple Myeloma

Yanyan Gu, MD PhD, Benjamin G Barwick, PhD, Mala Shanmugam, PhD, Craig C Hofmeister, MDMPH, Jonathan L. Kaufman, MD, Ajay K Nooka, MDMPH, Vikas A. Gupta, MD PhD, Madhav V Dhodapkar, MBBS, Lawrence H. Boise, PhD, Sagar Lonial

Blood (2019) 134 (Supplement_1): 5499.

https://doi.org/10.1182/blood-2019-128216

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Pallavi Mehta, MD DM, Neha Yadav, BDS , MBA, Mohan Bhaarat, Sumeet Prakash Mirgh, MBBS, MDDM, Vishvdeep Khushoo, MBBS, MDDM, Shinto Francis Thekuddan, MBBS, MDDM, Narendra Agrawal, MD DM, Rayaz Ahmed, MDDM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 5572.

https://doi.org/10.1182/blood-2019-131674

Published: 2019

Journal Articles

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Thura Win Htut, MBBS, MRCP, Donald P. Quick, MD, Myint Aung Win, MDMBBS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Somedeb Ball, MD, Ei Moe Phyu, MD, Nyein Htway Yu, MBBS, MD, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Nicholas D'Cunha, MD, Sanjay Awasthi, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5550.

https://doi.org/10.1182/blood-2019-123156

Published: 2019

Journal Articles

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Christopher Tor Sauter, MD, Luca L Bernabei, BA, Adam Waxman, MD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Dan T. Vogl, MD, Sara Whittington,, RN, MPH, Colleen Harker Erb, CRNP, Patricia Mangan, CRNP, Mary Sanchez, CRNP, Edward A. Stadtmauer, MD FACP

Blood (2019) 134 (Supplement_1): 5598.

https://doi.org/10.1182/blood-2019-132087

Published: 2019

Journal Articles

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Alexander Vdovin, Tomas Jelinek, MD, Matous Hrdinka, PhD, Juli R. Bago, PhD, Tereza Sevcikova, Roman Hajek, Prof, MD PhD, Michal Simicek, PhD

Blood (2019) 134 (Supplement_1): 5526.

https://doi.org/10.1182/blood-2019-127930

Published: 2019

Journal Articles

Quantitative PK/PD Prediction of the Efficacious and Safe Dose Ranges of the LMP7 Inhibitor M3258 for Phase I Application in Relapsed/Refractory Multiple Myeloma Patients

Florian Lignet, Christina Esdar, Manja Friese-Hamim, Andreas Becker, Elise Drouin, Samer El Bawab, Samantha M. Goodstal, Claude Gimmi, Phlipp Haselmayer, Frank Jährling, Michael Sanderson, Willem Sloot, Sofia Stinchi, Anja Victor, Gina Walter, Felix Rohdich

Blood (2019) 134 (Supplement_1): 5582.

https://doi.org/10.1182/blood-2019-126972

Published: 2019

Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5534.

https://doi.org/10.1182/blood-2019-132001

Published: 2019

Journal Articles

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

Ye Yang, PhD, Yongqiang Zhu, Chunyan Gu

Blood (2019) 134 (Supplement_1): 5586.

https://doi.org/10.1182/blood-2019-127927

Published: 2019

Journal Articles

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

Yan Xu, MD, Matthew Ho, PhD, Mehmet Kemal Samur, PhD, Kenneth Wen, Shuhui Deng, MD, Lanting Liu, MD, Tengteng Yu, MD PhD, Zuzana Chyra, PhD, Sanika Derebail, Kenneth C. Anderson, MD, Lugui Qiu, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 5539.

https://doi.org/10.1182/blood-2019-130902

Published: 2019

Journal Articles

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Blood (2019) 134 (Supplement_1): 4204.

https://doi.org/10.1182/blood-2019-126538

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Brianna Craver, MS, Quy Nguyen, Gajalakshmi Ramanathan, PhD, Angela G. Fleischman, MD PhD

Blood (2019) 134 (Supplement_1): 2518.

https://doi.org/10.1182/blood-2019-123480

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

GPS2 promotes erythroid differentiation by control of the stability of EKLF protein

A master erythroid regulator gets its own GPS

Synergistic Effect of Carfilzomib and Metformin in Vascular Plasticity; The Emerging Role of Autophagy

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Comprehensive Geriatric Assessment in Consecutive Newly-Diagnosed Elderly Multiple Myeloma Patients in China: A Multicentered, Prospective, Non-Interventional Study

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

The Role of Proteasome Activator PA28α in Multiple Myeloma

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Carfilzomib-Pomalidomide-Dexamethasone (KPD) in Relapsed/Refractory Multiple Myeloma Patients - an Institutional Retrospective Analysis

Incidence of Second Primary Malignancies and Peripheral Sensory Neuropathy in Patients with Multiple Myeloma Receiving Daratumumab Containing Regimen

Infectious Complications Following Venetoclax-Proteasome Inhibitor Based Regimens in Relapsed Myeloma: A Single Center Retrospective Analysis

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Quantitative PK/PD Prediction of the Efficacious and Safe Dose Ranges of the LMP7 Inhibitor M3258 for Phase I Application in Relapsed/Refractory Multiple Myeloma Patients

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

The Efficacy of a Novel Oral Proteasome Inhibitor NNU546 in Multiple Myeloma

Ywhae/14-3-3ε Expression Promotes Translation Initiation and Protein Synthesis in Multiple Myeloma Regulating Proteasome Load and Contributing to Proteasome Inhibitor Sensitivity/Resistance

In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only